Low-grade gliomas (LGGs) are the most common CNS tumors, and the main therapy for LGGs is complete surgical resection, due to its curative effect. However, LGG recurrence occurs frequently. Biomarkers play a crucial role in evaluating the recurrence and prognosis of LGGs. Numerous studies have focused on LGG prognosis. However, the multiomics research investigating the roles played by gene methylation and expression in LGG recurrence remains limited. In this study, we integrated the TCGA and GEO datasets, analyzing RNA and methylation data for recurrence (R) and nonrecurrence (NR) groups. We found a low expression of TLX1NB and high methylation in recurrence patients. Low expression of TLX1NB is associated with poor survival (OS: ). The expression of TLX1NB is likely to play a role in the prognosis of LGG. Therefore, TLX1NB may represent an alternative early biomarker for the recurrence of low-grade gliomas.

中文翻译：

---

失调的表达和甲基化分析鉴定为低级胶质瘤的新型复发标志物TLX1NB。

低度神经胶质瘤（LGGs）是最常见的中枢神经系统肿瘤，由于其疗效，LGGs的主要治疗方法是完全手术切除。但是，LGG复发经常发生。生物标志物在评估LGG的复发和预后中起着至关重要的作用。许多研究集中于LGG的预后。但是，有关基因甲基化和表达在LGG复发中所起的作用的多组学研究仍然有限。在这项研究中，我们整合了TCGA和GEO数据集，分析了复发（R）和非复发（NR）组的RNA和甲基化数据。我们发现在复发患者中TLX1NB的低表达和高甲基化。TLX1NB的低表达与存活率低有关（OS：）。TLX1NB的表达可能在LGG的预后中发挥作用。因此， TLX1NB可能代表低级神经胶质瘤复发的替代早期生物标志物。